Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2003-09-19 (22 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BOUILLARGUES (30230), Gard
SELARL PHARMACIE LAFITTE : revenue, balance sheet and financial ratios
SELARL PHARMACIE LAFITTE is a French company
founded 22 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BOUILLARGUES (30230),
this company of category PME
shows in 2023 a revenue of 2.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE LAFITTE (SIREN 450070586)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
1 998 757 €
1 897 938 €
1 736 156 €
N/C
N/C
N/C
1 377 761 €
Net income
138 872 €
112 161 €
119 957 €
167 025 €
150 607 €
149 154 €
140 768 €
109 056 €
107 626 €
EBITDA
N/C
N/C
172 340 €
209 945 €
205 257 €
N/C
N/C
N/C
155 809 €
Net margin
N/C
N/C
6.0%
8.8%
8.7%
N/C
N/C
N/C
7.8%
Revenue and income statement
In 2025, SELARL PHARMACIE LAFITTE generates positive net income of 139 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 108 k€ -> 139 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
138 872 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 27%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
27.156%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
66.904%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
9.238
8.249
10.504
14.421
12.0
27.089
28.392
27.381
27.156
Financial autonomy
72.389
71.194
77.302
75.435
78.056
66.846
66.807
66.61
66.904
Repayment capacity
0.651
None
None
None
0.713
1.643
1.883
None
None
Cash flow / Revenue
8.202%
None%
None%
None%
8.783%
8.102%
6.885%
None%
None%
Sector positioning
Debt ratio
27.162025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good
In 2025, the debt ratio of SELARL PHARMACIE LAFITTE (27.16) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
66.9%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good-5 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE LAFITTE (66.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
1.88 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SELARL PHARMACIE LAFITTE (1.88) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 238.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
127.922
126.643
184.763
229.072
247.923
195.618
207.099
209.999
238.746
Interest coverage
0.512
None
None
None
0.061
0.157
0.677
None
None
Sector positioning
Liquidity ratio
238.752025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good+13 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE LAFITTE (238.75) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.68x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE LAFITTE (0.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE LAFITTE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
113 665 €
0 €
0 €
0 €
138 233 €
208 375 €
217 305 €
0 €
0 €
Inventory turnover (days)
28
0
0
0
25
28
29
0
0
Customer payment term (days)
8
0
0
0
5
10
7
0
0
Supplier payment term (days)
64
0
0
0
33
45
39
0
0
Positioning of SELARL PHARMACIE LAFITTE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE LAFITTE is estimated at
2 205 998 €
(range 1 497 000€ - 3 461 514€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1497k€2205k€3461k€
2 205 998 €Range: 1 497 000€ - 3 461 514€
NAF 5 année 2025
Valuation method used
Net Income Multiple
138 872 €
×
15.9x
=2 205 998 €
Range: 1 497 001€ - 3 461 515€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE LAFITTE with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE LAFITTE
What is the revenue of SELARL PHARMACIE LAFITTE ?
The revenue of SELARL PHARMACIE LAFITTE in 2023 is 2.0 M€.
Is SELARL PHARMACIE LAFITTE profitable?
Yes, SELARL PHARMACIE LAFITTE generated a net profit of 139 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE LAFITTE ?
The headquarters of SELARL PHARMACIE LAFITTE is located in BOUILLARGUES (30230), in the department Gard.
Where to find the tax return of SELARL PHARMACIE LAFITTE ?
The tax return of SELARL PHARMACIE LAFITTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE LAFITTE operate?
SELARL PHARMACIE LAFITTE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart